Is Agios Pharmaceuticals, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Agios Pharmaceuticals, Inc. has changed from very attractive to attractive, indicating a shift in market perception. The company appears to be undervalued, with a P/E ratio of 4, a PEG ratio of 0.01, and an EV to EBITDA ratio of -3.81, which suggests that the stock may be trading at a significant discount relative to its earnings potential.
In comparison to its peers, Agios has a lower P/E ratio than PTC Therapeutics, Inc. at 5.85 and Crinetics Pharmaceuticals, Inc. at -8.95, indicating that it is relatively cheaper in terms of earnings. The company's return performance shows a 1-week return of 4.24% compared to the S&P 500's 1.70%, and a year-to-date return of 28.82% against the S&P 500's 13.30%, which reinforces the notion that the stock may be undervalued.